As per the research report, the Asia Pacific Breast Biopsy Market size was predicted at USD 119.26 million in 2021. It is further forecasted to be growing at a CAGR of 11.3% and worth USD 203.69 million by 2026.
Factors such as an increase in the number of breast cancer screening programs as a result of government efforts, as well as an increase in demand for minimally invasive and non-invasive procedures due to various benefits such as faster recovery and less pain, are primarily expected to fuel the breast biopsy market in the Asia-Pacific. Under the supervision of ultrasound, a 6mm Bergstrom side-cutting biopsy needle was a successful instrument for obtaining large parts of the tissue. Increased awareness of early detection of breast cancer and improved reimbursement circumstances are also driving market expansion.
Furthermore, the increase in population, healthcare expenditure, and increase in public-sector measures to address female health issues benefit the market for breast biopsy devices. New instruments and procedures have substantially impacted the breast biopsy market's overall growth. In the medical industry, identifying cancer cells and DNA fragments has been a problem; nevertheless, the introduction of liquid biopsy has aided medical practitioners in precisely identifying circulating tumor cells. The liquid biopsy is capable of identifying all of the genetic complexity of cancers seen in human breasts and preventing them from migrating to other parts of the body. The appeal of the liquid biopsy has created a lucrative opportunity for the overall APAC breast biopsy market's growth.
The risk of infection associated with the use of biopsy needles, as well as the market's demanding regulatory approval procedures, are projected to restrict expansion. Breast biopsy instruments are expected to face challenges in the forecast period due to underdeveloped healthcare infrastructure and a lack of resources in this nation. Some over-the-counter medications, herbs, medicines, vitamins, and mineral supplements must be avoided after surgery because they may conflict with the medication given during the biopsy. The disease worsens if the patient does not follow the medical practitioner's advice. Such difficulties are essential stumbling blocks to the Breast biopsy market's overall expansion. The market's high cost is also stifling the procedure's high cost, risk, and adverse side effects.
This research report on the Asia-Pacific breast biopsy market has been segmented and sub-segmented into the following categories:
By Type:
By Product:
By Guidance:
By Country:
Asia-Pacific is expected to have a significant share during the forecast period in the worldwide breast biopsy market. This is because breast cancer screening programs are becoming more prevalent. The Asia-Pacific breast biopsy market is being driven by the rapid evolution of healthcare infrastructure in growing nations such as China, India, and South Korea, which has resulted in significant investments in advanced systems by hospitals and breast clinics. Apart from that, factors such as the rising prevalence of breast cancer, the increasing awareness among people, and funding for breast cancer research are fuelling the market growth in the region. Growing acceptance for improved medical technologies, as well as increased development by cancer diagnostics organizations, is a prominent factor driving the breast biopsy market. A significant driver boosting the breast biopsy market during the forecast period is the rising acceptance of modern medical technologies and increased development by companies involved in cancer diagnosis.
KEY MARKET PLAYERS:
Companies playing a significant role in the APAC breast biopsy market profiled in the report are Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Biopsy needles
5.1.3 Guidance systems
5.1.4 Biopsy tables
5.1.5 Localization wires
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Product
5.1.8 Market Attractiveness Analysis, By Product
5.1.9 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Needle breast biopsy
5.2.2.1 Core needle biopsy
5.2.2.2 Fine needle aspiration biopsy
5.2.2.3 Vacuum assisted biopsy
5.2.3 Open surgical breast biopsy
5.2.3.1 Excisional breast biopsy
5.2.3.2 Incisional breast biopsy
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3 Guidance
5.3.1 Introduction
5.3.2 Mammography-Guided Stereotactic Breast Biopsy
5.3.3 Ultrasound-Guided Breast Biopsy
5.3.4 MRI-Guided Breast Biopsy
5.3.5 Other Guidance Techniques
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Guidance
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Guidance
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Guidance
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Hologic Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Leica Biosystems Nussloch GmbH
8.3 C. R. Bard Inc.
8.4 Becton and Dickinson Company
8.5 Argon Medical Devices
8.6 Cook Medical Incorporated
8.7 Encapsule medical Devices LLC.
8.8 Ethicon Endo Surgery
8.9 Intact Medical Corporation
8.10 Galini SRL
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
